INmune Bio (INMB) stock

Worth $34.1MShares as of Nov 5

$1.10

-2.65%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score INMB. It is too small for a fair Quality Score.

Healthcare · Biotech

Next2026“…data analyses for the phase III trial required for substantive approval, which is expected to open in 2026…”Trial data · SEC filing · Jun 23

Follow INMB's news. Pro members can get an alert when INmune Bio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when INMB files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for INMB, and how long its cash lasts

Next step the company has named

2026“their advice regarding data analyses for the phase III trial required for substantive approval, which is expected to open in 2026.”Trial data · SEC filing · Jun 23

What it means: the first look at a trial’s main results, as the company reports them.

For Pro members: 6 more milestones and 87 filings.

Cash runway

The company says its cash lasts through year-end 2026 (8-K, Jan 27).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed May 1, 2024)
At-the-market share sales program (424B5, filed Dec 19, 2025)

For Pro members: 8 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when David Moss buys or sells

For Pro members: every trade, and David Moss’s 11 filings and quotes.

Get an alert when INMB files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

INMB's latest filings

Quarterly report10-Q, filed Nov 5
DATED OCTOBER 28, 20268-K, filed Oct 29
Prospectus for a sale of securities424B5, filed Oct 29

33 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why INMB isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. INMB is worth about $34.1M. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.